Personalis (PSNL)
(Delayed Data from NSDQ)
$1.45 USD
-0.01 (-0.68%)
Updated May 21, 2024 04:00 PM ET
After-Market: $1.46 +0.01 (0.69%) 7:54 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Personalis (PSNL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.60 | $7.50 | $3.50 | 215.07% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Personalis comes to $4.60. The forecasts range from a low of $3.50 to a high of $7.50. The average price target represents an increase of 215.07% from the last closing price of $1.46.
Analyst Price Targets (5 )
Broker Rating
Personalis currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on five recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 16.67% of all recommendations. A month ago, Strong Buy made up 60%, while Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.60 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
4/30/2024 | Lake Street Capital Markets | Thomas Flaten | Not Available | Strong Buy |
4/11/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
1/7/2024 | BTIG | Mark Massaro | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 6 |
Average Target Price | $4.60 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 63 of 252 |
Current Quarter EPS Est: | -0.34 |